Bausch & Lomb, Croma Pharma to co-promote bromfenac in some European markets

ROCHESTER, N.Y. — Croma Pharma, an Austrian-based health care company with ophthalmic interests, has granted several Bausch & Lomb subsidiaries co-promotion rights to sell bromfenac ophthalmic solution once it becomes available in certain European markets, Bausch & Lomb announced in a press release.

This follows Croma's submission of bromfenac to the European Medicines Agency for centralized approval throughout the European Union. Bromfenac has already received approval in the United States, where it is licensed by Ista, and in Japan, where it is licensed by Senju Pharmaceutical.

"We are enthusiastic about the collaboration with Croma, as we look forward to making bromfenac available in a large number of markets to support the unmet needs of patients and physicians alike," Charl van Zyl, vice president of pharmaceuticals for Bausch & Lomb's Europe, Middle East and Africa region, said in the release. "The addition of bromfenac to the European portfolio strengthens our customer offering and further invigorates our anti-inflammatory business by providing access to a new pan-European prescription brand."

Bausch & Lomb and Croma have announced plans to market bromfenac under a unique brand name in Austria, France, Poland, Romania and Spain. Financial terms of the agreement have not been disclosed.